Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)

被引：0
作者：
Yau, T. [1 ]
Meyer, T. [2 ]
Kelley, R. K. [3 ]
Mangeshkar, M. [4 ]
Cheng, A-L. [5 ]
El-Khoueiry, A. B. [6 ]
Abou-Alfa, G. K. [7 ]
机构：
[1] Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[2] Royal Free Hosp, Oncol, London, England
[3] USCSF Hellen Diller Family Comprehens Canc Ctr, Med, San Francisco, CA USA
[4] Exelixis, Biostat, Alameda, CA USA
[5] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[6] Univ Southern Calif, Norris Comprehens Canc Ctr, Med Oncol, Los Angeles, CA USA
[7] Mem Sloan Kettering Canc Ctr, Oncol, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
133P
引用
收藏
页数：1
相关论文
共 50 条
[21]   Quality-Adjusted Life Years Accrued with Cabozantinib in Patients with Advanced Hepatocellular Carcinoma (AHCC) in the CELESTiAL Trial [J].
Venerito, Marino ;
Abou-Alfa, G. K. ;
Mollon, P. ;
Meyer, T. ;
Cheng, A. -L ;
El-Khoueiry, A. B. ;
Kelley, R. K. ;
Baron, A. D. ;
Benzaghou, F. ;
Valcheva, V. ;
Hazra, S. ;
Mangeshkar, M. ;
Freemantle, N. .
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 :61-61
[22]   Quality-adjusted life years accrued with cabozantinib in patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial [J].
Trojan, J. ;
Abou-Alfa, G. K. ;
Mollon, P. ;
Meyer, T. ;
Cheng, A. -L. ;
El-Khoueiry, A. B. ;
Kelley, R. K. ;
Baron, A. D. ;
Benzaghou, F. ;
Valcheva, V. ;
Hazra, S. ;
Mangeshkar, M. ;
Freemantle, N. .
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 :241-241
[23]   Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial [J].
Waidmann, O. ;
Abou-Alfa, G. K. ;
Meyer, T. ;
Cheng, A-L ;
El-Khoueiry, A. B. ;
Rimassa, L. ;
Ryoo, B-Y ;
Cicin, I ;
Merle, P. ;
Chen, Y. H. ;
Park, J-W ;
Blanc, J-F ;
Bolondi, L. ;
Klumpen, H-J ;
Chan, S. L. ;
Dadduzio, V ;
Hessel, C. ;
Borgman-Hagey, A. E. ;
Schwab, G. ;
Kelley, R. K. .
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 :254-254
[24]   Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial. [J].
Abou-Alfa, Ghassan K. ;
Meyer, Tim ;
Cheng, Ann-Lii ;
El-Khoueiry, Anthony ;
Rimassa, Lorenza ;
Ryoo, Baek-Yeol ;
Cicin, Irfan ;
Merle, Philippe ;
Chen, Yen-Hsun ;
Park, Joong-Won ;
Blanc, Jean-Frederic ;
Bolondi, Luigi ;
Klumpen, Heinz Josef ;
Chan, Stephen Lam ;
Dadduzio, Vincenzo ;
Hessel, Colin ;
Borgman-Hagey, Anne E. ;
Schwab, Gisela ;
Kelley, Robin Kate .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[25]   Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma [J].
Kelley, Robin Kate ;
Meyer, Tim ;
Rimassa, Lorenza ;
Merle, Philippe ;
Park, Joong-Won ;
Yau, Thomas ;
Chan, Stephen L. ;
Blanc, Jean-Frederic ;
Tam, Vincent C. ;
Tran, Albert ;
Dadduzio, Vincenzo ;
Markby, David W. ;
Kaldate, Rajesh ;
Cheng, Ann-Lii ;
El-Khoueiry, Anthony B. ;
Abou-Alfa, Ghassan K. .
CLINICAL CANCER RESEARCH, 2020, 26 (18) :4795-4804
[26]   Association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma in the Phase III CELESTIAL trial [J].
Strasser, S. ;
Abou-Alfa, G. ;
Meyer, T. ;
Cheng, A. ;
Cicin, I. ;
Bolondi, L. ;
Klumpen, H. ;
Chan, S. ;
Zagonel, V. ;
Milwee, S. ;
Dubey, S. ;
Kelley, R. ;
El-Khoueiry, A. .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 :33-34
[27]   Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced Hepatocellular Carcinoma (HCC) [J].
Waidmann, O. ;
Merle, P. ;
Rimassa, L. ;
Ryoo, B-Y ;
Cicin, I ;
Harris, W. P. ;
Nemunaitis, J. ;
Olteanu, S. ;
Sarker, D. ;
Tan, B. R. ;
Van Vlierberghe, H. ;
Sen, S. ;
Love, C. ;
Cheng, A-L ;
El-Khoueiry, A. B. ;
Meyer, T. ;
Kelley, R. K. ;
Abou-Alfa, G. K. .
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 :283-284
[28]   Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC) [J].
Merle, P. ;
Rimassa, L. ;
Ryoo, B. ;
Cicin, I. ;
Harris, W. ;
Banu, E. ;
Sarker, D. ;
Tan, B. ;
Van Vlierberghe, H. ;
Sen, S. ;
Love, C. ;
Cheng, A. ;
Meyer, T. ;
Kelley, R. ;
Abou-Alfa, G. .
ANNALS OF ONCOLOGY, 2018, 29 :104-104
[29]   Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial. [J].
Abou-Alfa, Ghassan K. ;
Mollon, Patrick ;
Meyer, Tim ;
Cheng, Ann-Lii ;
El-Khoueiry, Anthony B. ;
Kelley, Robin Kate ;
Baron, Ari David ;
Benzaghou, Fawzi ;
Valcheva, Velichka Valerieva ;
Hazra, Saswati ;
Mangeshkar, Milan ;
Freemantle, Nicholas .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[30]   Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials. [J].
Llovet, Josep M. ;
Singal, Amit G. ;
Villanueva, Augusto ;
Finn, Richard S. ;
Kudo, Masatoshi ;
Galle, Peter R. ;
Wang, Chunxiao ;
Widau, Ryan C. ;
Gugel, Elena Gonzalez ;
Zhu, Andrew X. .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345